Monthly information on share capital and company voting rights
On May 16, 2024, Cellectis released its monthly update on share capital and voting rights as stipulated by Article 223-16 of the French financial markets authority.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On May 16, 2024, Cellectis released its monthly update on share capital and voting rights as stipulated by Article 223-16 of the French financial markets authority. The company, listed on Euronext Growth under the ISIN code FR0010425595, reported a total of 99,955,535 shares in its capital and 87,891,239 voting rights as of May 3, 2024. For more details, the company provided contact information for their media and investor relations teams.
Positive
- Total of 99,955,535 shares in capital indicates strong investor interest and market presence.
- Consistent updates on share capital and voting rights show transparency and regulatory compliance.
Negative
- The 87,891,239 voting rights are lower than the total number of shares, indicating possible restrictions or non-voting shares.
Details
News Market Reaction – CLLS
The recorded move for CLLS in the trading session of this news was -1.64%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
(Article 223-16 of General Regulation of the French financial markets authority)
PARIS, May 16, 2024 (GLOBE NEWSWIRE) --
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital | Total number of voting rights |
| 05/03/2024 | 99,955,535 | 87,891,239 |
For further information on Cellectis, please contact:
Media contact:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@cellectis.com
Investor Relations contacts:
Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.